Lexaria Bioscience (NASDAQ:LEXX) (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.
Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets. The company pursues partnerships and licensing agreements with industry participants to incorporate its delivery technology into a range of finished goods, including functional foods, beverages and over-the-counter formulations. In addition to cannabinoids, Lexaria has extended its research to nicotine and vitamin molecules, reflecting a strategy to serve multiple end-use sectors.
Lexaria’s research efforts include preclinical and clinical investigations to validate the efficacy and safety of its technology. The company has collaborated with academic and contract research organizations in North America to conduct pharmacokinetic and toxicology studies. These studies support regulatory filings and form the foundation for future pharmaceutical and nutraceutical product launches.
Leadership at Lexaria is led by President and Chief Executive Officer Christopher Bunka, who oversees the company’s strategic direction, partnerships and product development initiatives. Backed by a team with expertise in pharmaceutical sciences, regulatory affairs and commercial operations, Lexaria Bioscience continues to advance its mission of delivering next-generation oral absorption technologies to the global health, wellness and therapeutic markets.
